Aim: Intranasal aerosol administration of drugs is widely used by ENT specialists. Although clinical evidence is still lacking, intranasal nebulization appears to be a promising therapeutic option for local drug delivery, targeting anatomic sites beyond the nasal valve. The sonic nebulizer NL11SN associates a 100 Hertz (Hz) sound to the aerosolization to improve deposition in the nasal/paranasal sinuses. The aim of the present study was 1) to evaluate in vivo the influence of associating a 100Hz sound on sinus ventilation and nasal and pulmonary aerosol deposition in normal volunteers, and 2) to quantify in vitro aerosol deposition in the maxillary sinuses in a plastinated head model. Tc-DTPA particles nebulized with the NL11SN were deposited predominantly in the nasal cavities (2/3, vs. 1/3 in the lungs). In vitro, the use of NL11SN in sonic mode increased gentamicin deposition threefold in the plastinated model sinuses (p<0.002); the resulting antibiotic deposit would be sufficient to induce a local therapeutic effect.
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Introduction
Although the efficacy of nebulizing pulmonary antibiotics and corticosteroids has been demonstrated in many studies [1, 2] , nebulization of antibiotics with a nasal target remains controversial [3, 4] . The French health products safety agency AFSSAPS does not recognize an indication for local antibiotics in rhinosinus pathology [5] . In theory, however, nebulization has the advantage over classic administration routes of delivering the drug directly to the target organ, thereby avoiding systemic side-effects while increasing the local dose. Consequently, despite a relative lack of clinical evidence and the small number of published studies, nasal nebulization is in fact frequently used in ENT and by family doctors [6, 7] . Nasal aerosol therapy is used in most acute and chronic nasal cavity and sinus pathologies, enabling direct application to the rhinosinusal mucosa, with a rapid clinical response and minimal side-effects. It is particularly used in failure of reference per os or spray treatment [6, 8] . Nebulization may indeed be an interesting treatment option in nasal antibiotherapy [9, 10] .
There are currently no nasal antibiotic sprays; sprays, moreover, fail to target potentially infected anatomic sites such as the maxillary sinus, ethmoid cells or middle turbinate [11, 12] .
As nebulizers produce finer particles than sprays (4µm vs. 30µm), they can target anatomic areas beyond the nasal valve, but still fail to reach the maxillary sinuses. Associating a 100Hz acoustic wave, however, enhances ventilation [13] and aerosol deposition [14] in the sinonasal cavities. Nasal sonic nebulizers would thus seem to generate the best adapted aerosols for local treatment of rhinosinusitis.
The present study sought to quantify respiratory pathway and maxillary sinus deposition of the aerosol produced by a nasal sonic nebulizer, NL11SN (DTF, Saint Etienne, France) designed to optimize nasal cavity and maxillary sinus deposition by associating a 100 Hz 2.2. Healthy volunteer scintigraphy study.
Study population
This single-center study included 7 healthy male, non-smoking volunteers aged 21 to 36 years, with a mean height of 181 ± 3 cm and mean weight 77 ± 10 kg.
The study design was approved by the ethics committee of the Saint Luc University Clinics of the Catholic University of Leuven (UCL, Belgium), where the study was performed. In line with the Declaration of Helsinki and good clinical practice guidelines, the healthy volunteers signed their written informed consent before final inclusion.
The subjects were judged healthy at the first selection consultation after a complete medical check-up comprising physical examination, vital signs assessment, medical and surgical history and inclusion/exclusion criteria: the pulmonary scintigraphy examination required hal-00757723, version 1 -28 Nov 2012 subjects to be equivalent in sex, age, height and weight so as to limit and harmonize thoracic tissue attenuation within the study population.
The main grounds for exclusion were history of cardiovascular pathology, allergy, asthma or other pulmonary pathology or any ENT, and especially rhinosinusal, pathology (polyposis or any type of rhinosinusitis) or ENT or head and neck surgery (whether repair or functional).
The clinical examination was completed by nasal cavity rhinoscopy; subject 3 showed right nasal deviation and subject 5 a right septal spur, but these were considered to be anatomic variants not entailing exclusion.
Scintigraphic ventilation study of the contribution of a 100 Hz sound
Krypton 81m ( 81m Kr) ventilation was performed to study the effect on maxillary sinus penetration of associating a 100 Hz sound and to determine the anatomic upper airway and lung regions. Kr generator, Covidien, Petten, Netherlands) was continuously administered via nasal plugs to achieve upper and lower airway ventilation.
The following 2-min scintigraphic acquisitions were performed using a STARPORT 400 AC/T gamma camera (General Electric, Horsholm, Denmark):
• Gas-1: nasal cavities on right lateral head view;
• Gas-2: nasal cavities on AP head view on ventilation without sound;
• Gas-3: nasal cavities on AP head view on ventilation with 100 Hz sound;
• Gas-4: lungs on posterior thorax view.
Sonic 99m
Tc-DTPA aerosol deposition study
The NL11SN nebulizer was loaded with a 3 ml solution containing 25mg DTPA (DiethyleneTriamine Penta-Acetic Acid) with 74 MBq Technetium 99m ( 
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Ahead of the aerosol session, subjects were trained to inhale the aerosol by the nose and breathe out by the mouth. An absolute filter system (BB50TE, Pall Medical, France) protected the ambient air and quantified exhaled aerosol activity. Nebulization was associated to a 100
Hz sound for 10 minutes.
Immediately after inhalation, the subject sat face to the camera for 3 acquisitions:
• Aerosol-1: nasal cavities on right lateral head view;
• Aerosol-2: thorax on posterior view;
• Aerosol-3: residual nebulizer and accessory activity.
Image processing
Total deposited airway activity was calculated on the activity-balance method, consisting in subtracting non-deposited activity from the activity initially introduced in the nebulizer.
Results were corrected for background noise and radioactive decay.
Regions were traced around the anatomic areas of interest (nasal cavities, lungs, stomach) from the ventilation images and applied to each deposition image. Percentage aerosol deposition per region of interest was calculated from the total deposited activity. Deposited DTPA mass (µg) was also determined for each region from the DTPA mass initially introduced in the nebulizer.
In vitro gentamicin sonic aerosol deposition study
Intrasinus concentrations of an antibiotic, gentamicin, nebulized with and without associated 100 Hz sound, were compared in a plastinated head anatomic model.
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The human head plastination technique developed and adapted for ENT modeling in the anatomy laboratory of the Saint-Etienne Medical School (France) was used to create several plastinated specimens, three of which were dedicated to functional sinonasal cavity studies [16, 17] .
The plastinated anatomic specimens were obtained following the usual stages of this technique: specimen preparation (3 days), formaldehyde fixation (3 months), dehydration and degreasing with acetone (1-2 months), silicone impregnation (10-20 days), and polymerization (2-3 months). The polymerization was optimized to avoid tissue retraction [17] . The plastinated heads were validated as aerosol deposition models after anatomic, geometric and aerodynamic analysis, using classical clinical techniques: rhinoscopy, endoscopy, CT, rhinomanometry and acoustic rhinometry.
The models' maxillary sinuses were opened using a sagittal cut involving the lateral sinus wall. Two movable plexiglass plates were used to close the sinuses hermetically during nebulization ( Figure 1 ). This gave access to the sinus antrum to collect the deposited aerosol.
Gentamicin nebulization
Gentamicin (Gentallin ® , Schering-Plough SAS, Courbevoie, France), an aminoglycoside active on Gram-negative bacteria and staphylococci, with recognized efficacy on the bacteria implicated in rhinosinusitis [18, 19] , was chosen as marker for its solidity and specific deposition on routine methods. Two concentrations were used: 40 and 80 mg/ml.
The NL11SN nebulizer was loaded with 4 ml gentamicin and connected to the model nostrils via nasal plugs (Figure 1 ).
Nebulization lasted 10 minutes. The plexiglass plates were then withdrawn and the maxillary sinuses were given 4 rinses of 1 ml physiological saline by syringe to collect the gentamicin hal-00757723, version 1 -28 Nov 2012
deposited on the sinus walls. The rinse liquid was kept at -20°C for subsequent measurement of the collected gentamicin.
After each nebulization, the specimen was liberally washed and dried in free air for at least 48 hours.
Nebulization (n= 112) was performed either in sonic mode (with 100 Hz sound) or classical mode (without sound). Physiological saline nebulization (n=34) was used to check wash-out:
i.e., that no gentamicin remained in the sinuses.
Gentamicin assay
Gentamicin was assayed on 291 sinus rinse liquid samples by immuno-enzymatic analysis (fluorescence polarization immunoassay) on a TDX/FLX® device (Abbott Diagnostics, Rungis, France). Assays were performed in triplicate using Gentamicin® reagents (Abbott Laboratories, Diagnostic Division, EU) with sensitivity of 0.27mg/L.
Statistical analysis
The impact of a 100 Hz sound on gentamicin sinus deposition in the plastinated head model was assessed by t test (XLSTATS®). The significance threshold was set at p<0.05.
Results
The in vivo inhalation sessions ( 
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The images also enabled anatomic regions to be defined in the upper airways and lungs, so as to quantify sonic aerosol deposition of nasally inhaled 99m TcDTPA ( Figure 1 , Aerosol-1).
In terms of 99m
Tc-DTPA mass, respiratory pathway aerosol distribution was 2,400 ± 475 µg in the upper airways (nasal cavities and rhinopharynx) and 925 ± 425 µg in the lungs, demonstrating effective targeting of the nasal cavities (two-thirds of the activity) as compared to the lungs. These upper airway calculations took account of swallowing and nasal clearance ( Table 1 ).
The images, however, showed only a small amount of aerosol in the maxillary sinuses, far less than the krypton seen to penetrate them under ventilation scintigraphy. Valid image processing to quantify maxillary region aerosol deposition precisely was not feasible due to the difficulty of situating the regions anatomically.
Little radioactive DTPA (0 ± 25 µg) was found in the stomach, indicating that little aerosol was swallowed during the nebulization session.
In vitro, the 112 gentamicin nebulizations and iterative rinsing did not affect the plastinated head anatomy. Absence of gentamicin in the sinuses was checked by assaying the sinusal liquid collected after physiological saline (result: < 0.27mg/l).
The results detailed in Table 2 show an up to 3-fold increase (p<0.05) in gentamicin concentration in the maxillary sinuses when the 100 Hz sound was associated to nebulization,
for both types of concentration tested. Deposition was significantly greater in the left than the right sinus, with or without associated sound (p<0.05).
Discussion
The interest of associating a 100 Hz sound to nasal administration was studied first directly in healthy volunteers by in vivo Kr ventilation) unlike in the general case of patients with rhinologic pathology: patients likely to be concerned by nasal antibiotherapy for chronic rhinosinusitis will generally have a closed ostium [21] .
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The second, in vitro, study examined the effect of associating a 100 Hz sound to a gentamicin aerosol in a plastinated human head model. Plastination provided a model conserving the mucosa, anatomy and aerodynamics of the nasal cavities and sinuses. Moreover, the active substances nebulized and deposited in the maxillary sinuses could be assayed in situ.
The results demonstrated that the gentamicin nebulized by the NL11SN penetrated and was deposited in the model's maxillary sinuses. The main factor affecting sinusal deposition was the 100 Hz sound, in presence of which the gentamicin concentration collected from the sinuses was significantly increased, by a factor of 1.6 to 3 ( Table 2 ). For a given gentamicin dose, the increase in sinus deposition was equivalent in the 2 sinuses, although the absolute amount of deposit was significantly different between the two (p<0.05), probably due to geometrical differences between the left and right maxillary sinus ostia. Rhinomanometric measurements taken on the same model showed greater right than left ostium resistance [17, 22] . The gain in maxillary gentamicin deposition provided by the associated sound was independent of ostium geometry.
Although the model enabled sinus deposits to be collected, it involved certain limitations. The gentamicin assay results were highly variable, due to the technical difficulty of rinsing the sinuses with physiological saline to collect the gentamicin. However well controlled the technique, sinus antrum anatomy and the uneven aerosol deposition over the cavities meant that collection was neither exhaustive nor strictly reproducible from one trial to another.
Moreover, sinus rinsing was suboptimal, as it included neither the lateral wall of the maxillary sinus nor any possible physical gentamicin absorption by the plastinated sinus mucosa; the real quantity of deposited gentamicin in the sinuses was therefore once again inevitably underestimated.
There was further a technical limitation inasmuch as the plastinated head specimen was not ventilated and thus was "passive" under aerosol administration. Inhalation and exhalation of the aerosolized particles was not reproduced, which may have affected the deposition kinetics as compared to a ventilated model. This lack of "respiration" might reduce or on the contrary increase sinus penetration: the former, as airflow through the nasal cavities under inspiration (acceleration) and expiration (vortex) maintains sinus aeration, enabling gas exchange with the nasal cavities (sinus respiration) [21,22,] ; or the latter, due to aerosol accumulation in the nasal fossae, increasing penetration into the maxillary sinuses via the ostia.
Nasal antibiotic nebulization is especially controversial due to a lack of data as to the quantity infection in mucoviscidosis patients. In vivo studies reported about 45 mg tobramycin deposited in the lungs using the reference pneumatic nebulizer [1] .
From these data, the tobramycin deposition rate in the lungs can be estimated at 0.0346 µg/cm 2 (for a maximum deposition area of 130 m 2 ).
If the maxillary sinus is assimilated to a sphere of about 17 cm 3 (mean = 15 to 20 cm 3 in the literature) [23, 24, 25] , the potential aerosol deposition area in a sinus will be 31.93 cm 2 .
Gentamicin deposition in the plastinated head sinuses was estimated at 0.05183 µg/cm 2 .
According to these new data, the quantity of gentamicin deposition in the in vitro model sinuses can be estimated as being 1.5 fold greater (0.05183 µg/cm 2 vs. 0.0346 µg/cm 2 ) than the reference aminoside deposition in the lungs. Thus, on this initial approach, the quantity of gentamicin collected from the maxillary sinuses would seem to be sufficient to induce a local anti-infection effect. These results should be confirmed in a clinical assessment of the therapeutic efficacy of antibiotic deposition by nasal sonic aerosol.
Conclusions
The present study showed that sonic nebulization (i.e., nebulization coupled to a 100 Hz sound), as implemented using the NL11SN nebulizer, optimized aerosol deposition in the nasal cavities (two-thirds of activity) and effectively targeted anatomic regions of interest such as the maxillary sinuses. Maxillary sinus penetration proves passage through the middle meatus, the center of sinus pathology. Thus the nasal sonic aerosols produced by the NL11SN can treat certain rhinosinus pathologies.
By comparison with the results for pulmonary deposition normalized per unit of tissue area, the amount of sinus drug deposition seems sufficient to induce a local anti-infection effect.
The plastinated human head seems to be a useful model for therapeutic assessment of the 
